Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Johansson, Pera; b; 1 | Mattsson, Niklasc; 1 | Hansson, Oskard | Wallin, Andersc | Johansson, Jan-Oveb | Andreasson, Ulfc | Zetterberg, Henrikc | Blennow, Kajc | Svensson, Johanb; e; *
Affiliations: [a] Department of Neuropsychiatry, Skaraborg Hospital, Falköping, Sweden | [b] Department of Endocrinology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden | [c] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg and Mölndal, Sweden | [d] Clinical Memory Research Unit, Clinical Sciences Malmö, Lund University, Lund, Sweden | [e] Department of Endocrinology, Skaraborg Hospital, Skövde, Sweden
Correspondence: [*] Correspondence to: Johan Svensson, M.D., Department of Endocrinology, Gröna Stråket 8, Sahlgrenska University Hospital, SE-413 45 Gröteborg, Sweden. Tel.: + 46 31 7411712; Fax: +46 31 821524; Email: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ)1-42, T-tau, and P-tau have good diagnostic accuracy for clinically diagnosed Alzheimer's disease (AD). However, in multi-center studies, the predictive values of the CSF biomarkers have been lower, possibly due to differences in procedures for lumbar puncture and CSF handling and storage, and to differences in patient populations, clinical evaluations, and diagnostic procedures. Here we investigate the diagnostic accuracy of CSF biomarkers in a well defined homogeneous mono-center population. We also evaluate an extended panel of amyloid related biomarkers. Sixty consecutive patients admitted for cognitive impairment to a memory clinic were recruited. The participants included patients with AD or mild cognitive impairment (MCI) diagnosed with AD upon follow-up (n = 32), patients with stable MCI (n = 13), patients with other dementias diagnosed at primary evaluation or upon follow-up (n = 15), and healthy controls (n = 20). CSF was analyzed for Aβ1-42, T-tau, P-tau, AβX-38, AβX-40, AβX-42, sAβPPα, and sAβPPβ. In multivariate analysis, the core biomarkers Aβ1-42, T-tau, and P-tau demonstrated a high ability to diagnose AD versus the combined groups of controls and stable MCI, with an area under the receiver operating characteristic curve (AUROC) of 0.97 (95% CI 0.93–1.00, p < 0.0001). The additional biomarkers only marginally increased AUROC to 0.98 (95% CI 0.95–1.00, p < 0.0001), this increase mainly mediated by AβX-42. In conclusion, CSF biomarkers Aβ1-42, T-tau, and P-tau have very high diagnostic accuracy in a well defined cohort of untreated patients, demonstrating the excellent potency of CSF biomarkers to identify pathological processes in AD when a stringent analytical protocol is used.
Keywords: Alzheimer's disease, amyloid, biomarkers, cerebrospinal fluid, diagnosis
DOI: 10.3233/JAD-2011-101878
Journal: Journal of Alzheimer's Disease, vol. 24, no. 3, pp. 537-546, 2011
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]